Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.7M
- Price
- $1.99
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.29%
- Volume
- 85.3K
About
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Quick stats
Shares outstanding5.9M
Computed float5.4M
Float / shares91.7%
Cash runway (months)2.7
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001995704
Websitehttps://www.cuprina.com.sg
AI Summary
AI-generated1/17
majorbullishm and a
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
Cuprina Holdings (Nasdaq: CUPR) signed agreements to acquire 100% of East Coast Podiatry Centre (five clinics) and Orchard Clinic Management (two clinics) for approximately S$4.0 million (~US$3.1 million).
The Target Group generated FY2025 unaudited revenue of S$9.1 million and normalized EBITDA of S$1.2 million per management accounts, with 75% of consideration in cash and 25% in locked-up Class A shares; closing is expected on or before November 1, 2026.
The deal gives Cuprina an established clinical platform aligned with its wound-care and collagen technologies, and Cuprina expects to consolidate the Target Group's financial results post-completion.
Red flags
- Target financials are unaudited management accounts and subject to adjustment upon audit
- partial share consideration implies dilution (S$1.0 million in Class A shares at S$3.31 reference price)
- completion subject to customary closing conditions